Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical marijuana company.
Revenue is forecast to grow 39.46% per year.
Earnings grew by 339.5% over the past year.
RISK ANALYSIS
Earnings are forecast to decline by an average of -14.4% per year for the next 3 years.
High level of non-cash earnings.
Highly volatile share price over past 3 months.
Significant insider selling over the past 3 months.
Disclaimer:
We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature,
and are therefore are unqualified to give investment recommendations.
Always do your own research and consult with a licensed investment professional before investing.
This communication is never to be used as the basis of making investment decisions, and it is for entertainment purposes only.
Revenue is forecast to grow 39.46% per year.
Earnings grew by 339.5% over the past year.
RISK ANALYSIS
Earnings are forecast to decline by an average of -14.4% per year for the next 3 years.
High level of non-cash earnings.
Highly volatile share price over past 3 months.
Significant insider selling over the past 3 months.
Disclaimer:
We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature,
and are therefore are unqualified to give investment recommendations.
Always do your own research and consult with a licensed investment professional before investing.
This communication is never to be used as the basis of making investment decisions, and it is for entertainment purposes only.